Four Northwell Health Hospitals Rated Among Nation’s Best in 2020-21 US News & World Report Rankings

Four Northwell Health hospitals received top-50 national ratings in 18 adult medical specialties in US News & World Report’s 2020-21 Best Hospital rankings. Three of those hospitals – North Shore University Hospital in Manhasset, Long Island Jewish Medical Center in New Hyde Park and Lenox Hill Hospital in Manhattan – rate among the top 10 hospitals in the New York metropolitan area and the entire state, according to US News’ analysis of more than 4,500 medical centers nationwide.

The rankings come in the wake of a pandemic in which New York State was particularly hard hit. Northwell Health treated more COVID patients than any other health system in the nation, including about 17,000 hospitalized patients. Including those who were seen in our emergency departments, urgent care centers and physician practices, the health system has treated more than 55,000 COVID patients in total. Its multidisciplinary approach made the difference in saving countless lives.

“These rankings reflect all of the hard work being accomplished by the clinical staff and the support teams that make Northwell hospitals so highly regarded both regionally and nationally – and a destination of choice for consumers,” said Michael J. Dowling, president and chief executive officer of Northwell Health. “We’ve just been through a seismic event that’s tested our health system’s staff, processes, resources and resiliency and I’m proud to say that it’s made us even stronger. We’re more mindful than ever of what’s important. Our mission has never been more vital or more aligned with the needs of the communities that we serve.”

North Shore University Hospital (NSUH) ranked fourth in the metro area and state and is Long Island’s top hospital, according to US News. The hospital was nationally recognized in nine adult specialties: diabetes and endocrinology (22nd best in the country), pulmonology (23rd), orthopedics (24th), cardiology and heart surgery (29th), geriatrics (31st), neurology and neurosurgery (36th), urology (38th), nephrology (48th) and gastroenterology (GI) and GI surgery (49th).

Long Island Jewish (LIJ) Medical Center ranked sixth in the metro area and state and was nationally recognized in five specialties: gynecology (10th), urology (20th), ear, nose and throat (27th), neurology and neurosurgery (28th) and orthopedics (47th).

Lenox Hill Hospital was the ninth-ranked medical center in the state (10th in the metro area) and achieved top-50 national ratings in three medical specialties: ear, nose and throat (32nd), diabetes and endocrinology (40th) and neurology and neurosurgery (44th). The hospital’s neurosurgery team was the subject of the highly-acclaimed Netflix docudrama “Lenox Hill.”

One other Northwell hospital received high marks from US News. Huntington Hospital was ranked 12th-best in the state and 14th in the region, and its orthopedics (48th) program achieved national status once again.

US News conducts a separate analysis of the nation’s best children’s hospitals. In the latest survey results released on June 16, Northwell’s Cohen Children’s Medical Center in New Hyde Park earned top 40 national rankings for exceptional care in nine pediatric specialties. The largest provider of pediatric health services in New York State, Cohen Children’s has been ranked among the nation’s top children’s hospitals by US News for 14 consecutive years.

This marks the 31st edition of US News’ Best Hospitals rankings. Its methodologies in most areas of care are based largely on objective measures such as risk-adjusted survival and discharge-to-home rates, volume, and quality of nursing, among other care-related indicators. US News evaluated more than 4,500 medical centers nationwide in 25 specialties, procedures and conditions to compile its 2020-21 rankings. In the 16 specialty areas, only 134 US hospitals were ranked in at least one specialty.

To see a complete listing of US News’ Best Hospitals rankings, visit Best Hospitals.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”